Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes.
People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.
Spray yourself with a DEET-based insect repellent and the mosquitoes will leave you alone. But why? They flee because of their intense dislike for the smell of the chemical repellent and not because DEET jams their sense of smell, report researchers at the University of California, Davis.
An opportunity to contribute to a major initiative to alleviate poverty in the world's poorest populations.
Doxycycline alone is more effective against the most common form of filariasis in Southeast Asia than the standard treatment, with significantly fewer side effects, according to a new study published in the May 1 issue of Clinical Infectious Diseases and currently available online.
Findings from a new study in Zanzibar, published January 23 in PLoS Neglected Tropical Diseases, pave the way for the World Health Organization (WHO) to recommend the mass co-delivery of three anti-parasitic drugs for the first time.
Though little known to most Americans, lymphatic filariasis, trachoma, leishmaniasis, onchocerciasis, schistosomiasis and other so-called neglected tropical diseases are responsible for severe health burdens, especially among the world's poorest people.
Sri Lankans infected with lymphatic filariasis (also known as elephantiasis) experience severe loss of income, social isolation, and devastating stigma resulting in emotional distress, delayed diagnosis, and avoidance of treatment.
Once-yearly administration of two anti-parasitic drugs to control lymphatic filariasis (elephantiasis) costs just $0.06 to $2.23 per person treated, making it comparatively inexpensive, according to a major new international study of treatment costs.
The World Health Organization (WHO) based Special Programme for Research and Training in Tropical Diseases (TDR) has adopted a new strategy for strengthening and expanding research to prevent and control 'infectious diseases of poverty.'
Weill Cornell Medical College scientist Dr. Carl Nathan has issued a bold call for reforming the pharmaceutical development and patent systems in order to increase the number of vaccines and drugs available to combat neglected diseases that are ravaging the world's poor.
Though little known outside the developing world, the disease called lymphatic filariasis wreaks havoc on millions of people by causing their limbs and genitals to fill with fluid and swell monstrously - the symptom commonly known as elephantiasis.
The World Health Organization (WHO) and a group of more than 25 partner organizations unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people.
Waterborne infectious diseases, which bring death and illness to millions of people around the world, could largely be consigned to history by 2015 if global health partnerships integrate their programmes, according to Alan Fenwick writing in Science.
China is slated to be officially declared free of the debilitating disease lymphatic filariasis, 15 years ahead of the global elimination target of 2020.
Clear evidence that Lymphatic Filariasis (LF, commonly known as elephantiasis) can be eliminated is reported in The Lancet. LF is one of the world's most disfiguring and disabling parasitic diseases, and the target of one of the largest global public health programs using mass drug administration (MDA).
Organizers of a 20-year global effort to eliminate a parasitic infection that is a leading cause of disability have an early victory to savor: a five-year Egyptian elimination campaign has mostly succeeded, according to a new report in the March 25 issue of The Lancet.
Achieving success in the global fight against the "big three" diseases - HIV/AIDS, tuberculosis and malaria, which together account for 5.6 million deaths a year - may well require a concurrent attack on the world’s most neglected tropical diseases, says a team of researchers in the international open access journal PLoS Medicine.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
Scientists at the Liverpool School of Tropical Medicine have proved that a single course of one antibiotic may hold the key to curing the parasitic worm disease Elephantiasis (lymphatic filariasis) that has been one of the most common causes of global disability since Biblical times.
A single course of one antibiotic can successfully treat elephantiasis (filariasis) - a parasitic worm disease that is one of the most common causes of global disability, concludes a study published in this week’s issue of The Lancet.
More than a billion people are at risk for infection with filarial nematodes, parasites that cause elephantiasis, African river blindness, and other debilitating diseases in more than 150 million people worldwide.